Results 201 to 210 of about 22,949 (256)

Safety and Effectiveness of Satralizumab in Japanese Patients with Neuromyelitis Optica Spectrum Disorder: A 30‑Month Interim Analysis of Post‑marketing Surveillance. [PDF]

Neurol Ther
Yamamura T, Isobe N, Kawachi I, Nohara C, Miyazaki Y, Tomita M, Kamei Y, Yamashita K, Nakahara J, Nakashima I, Fujihara K.   +10 more
europepmc   +1 more source

New and Emerging Artificial Urinary Sphincters for Male Stress Urinary Incontinence: From Gold Standard to Next Generation

Neurourology and Urodynamics, EarlyView.
ABSTRACT Introduction For more than four decades, the AMS‐800 has remained the clinical benchmark device for the treatment of male stress urinary incontinence (SUI). Although it remains the gold standard for male SUI, the AMS‐800 has continued to have limitations such as suboptimal post‐operative continence rates, fixed hydraulic pressure, need for ...
Erin C. Schnell, Connie N. Wang, Eric S. Rovner   +2 more
wiley   +1 more source

Safety and effectiveness of pregabalin controlled-release in Korean patients with peripheral neuropathic pain: A post-marketing surveillance data. [PDF]

Medicine (Baltimore)
Oh SI, Park JH, Oh SY, Moon JY, Kang JY, Choi JB, Lee BW.   +6 more
europepmc   +1 more source

Real‐World Safety and Effectiveness of Glatiramer Acetate in Patients With Multiple Sclerosis: Final Results of Post‐Marketing Surveillance in Japan

Neurology and Clinical Neuroscience, EarlyView.
ABSTRACT Background Glatiramer acetate is an injectable disease‐modifying therapy indicated for multiple sclerosis (MS). Aim To evaluate the real‐world safety and effectiveness of glatiramer acetate for MS in Japan. Methods A prospective, multicenter, observational, all‐case post‐marketing survey was conducted in Japan between November 2015 and March ...
Masaaki Niino, Eriko Hayashi, Mai Itani, Jun‐ichi Kira   +3 more
wiley   +1 more source

Post-Marketing Surveillance of Adverse Events Following Recombinant Zoster Vaccine - China, 2020-2023. [PDF]

China CDC Wkly
Li Y, Li K, Ren M, Li Y, Zhang L, Fan C, Zhang Z, Cao L, Yu W, Yin Z.   +9 more
europepmc   +1 more source

Evaluating the Evolving Real‐World Adverse Events of GLP‐1RAs Using FDA Adverse Event Reporting System (FAERS)

Obesity, EarlyView.
Web portal for interrogating Adverse Events of GLP‐1 RA in diabetes vs weight control/obesity. ABSTRACT Objective This study aimed to assess the spectrum and frequency of adverse events (AEs) linked to glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) using the US FDA Adverse Event Reporting System (FAERS).
David Stone, Mary Playdon, Stephen D. Hursting, Aik Choon Tan   +3 more
wiley   +1 more source

The safety and effectiveness of pegfilgrastim to reduce cancer chemotherapy-induced febrile neutropenia in real-world practice in Japan: a post-marketing surveillance study. [PDF]

Support Care Cancer
Shibata N, Kuwazawa H, Yasukawa T, Iwabuchi M, Saji S.   +4 more
europepmc   +1 more source

Post-marketing surveillance of tofacitinib in patients with ulcerative colitis in Japan: a post hoc analysis of safety and effectiveness in older (≥65 years) and younger (<65 years) patients. [PDF]

Intest Res
Matsuoka K, Yamamoto T, Matsuura M, Fujii T, Arai S, Endo Y, Sato K, Yuasa H, Mizuno Y, Kobayashi Y, Hisamatsu T.   +10 more
europepmc   +1 more source

Cell-Free and Concentrated Ascites Reinfusion Therapy (CART) Shows Enhanced Efficacy in Gynecological Cancer Patients: A Post-Marketing Surveillance Study. [PDF]

Ther Apher Dial
Tamura N, Hirayama T, Yoshida E, Terao J, Kawata M, Hiranuma K, Okumura T, Fujino K, Torii N, Soneda N, Murayama G, Kusaoi M, Yamaji K, Terao Y.   +13 more
europepmc   +1 more source

Post Marketing Surveillance

Thatha Usha, Durga Prasad Thammisetty, Y. Samuel, Pattubala Monika, Dasari Monish Kumar   +4 more
openaire   +1 more source